Company Overview
Snapshot
Founded in July 2008 by Jacob Bar-Tana, SyndromeX operates with 1–10 employees. The company focuses on developing pharmaceutical solutions and holds one patent, signaling its commitment to intellectual property in drug development.
Business overview
SyndromeX is a pharmaceutical company dedicated to developing drugs for metabolic syndrome and related conditions such as dyslipidemia, type-2 diabetes, obesity, hypertension, and atherosclerotic cardiovascular disease. The company's core technology aims to create an all-in-one therapy to reduce the number of medications metabolic syndrome patients typically need, serving the pharmaceutical and healthcare industries.
Strategic signal
In November 2016, Jacob Bar-Tana, the founder of SyndromeX, was recognized for his inventions, patents, and patent applications. This highlights the company's foundational strength in scientific innovation and its focus on intellectual property, which is crucial for pharmaceutical development and signals a long-term commitment to novel therapeutic solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is SyndromeX's primary focus?
- SyndromeX is a pharmaceutical company that develops drugs for metabolic syndrome and related diseases, including dyslipidemia, type-2 diabetes, obesity, hypertension, and atherosclerotic cardiovascular disease.
- When was SyndromeX founded?
- SyndromeX was founded in July 2008.
- Who is the founder of SyndromeX?
- Jacob Bar-Tana, MD, Ph.D. is the founder of SyndromeX.
- What is the company's product development stage?
- SyndromeX's products are currently in the Clinical Trial stage, as indicated by its product stage classification.
- What was a notable early technology development for SyndromeX?
- In July 2008, SyndromeX developed a single drug for the treatment of metabolic syndrome, categorized under Pharmaceuticals & Diagnostics.